¼¼°èÀÇ Çì¸ð±Û·Îºó A1C(HbA1C) °Ë»ç ½ÃÀå
Hemoglobin A1C (HbA1C) Testing
»óǰÄÚµå : 1760772
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 511 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,068,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,204,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Çì¸ð±Û·Îºó A1C(HbA1C) °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 23¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 15¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Çì¸ð±Û·Îºó A1C(HbA1C) °Ë»ç ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 8.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 23¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ À̿ ±³È¯ °í¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ(HPLC)´Â CAGR 8.6%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9¾ï 1,570¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¸é¿ªºÐ¼®¹ý ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 9.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 2,200¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR10.6%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Çì¸ð±Û·Îºó A1C(HbA1C) °Ë»ç ½ÃÀåÀº 2024³â¿¡´Â 4¾ï 2,200¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£2024-2030³â CAGR 10.6%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿©, 2030³â¿¡´Â 2¾ï 7,420¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 6.2%¿Í 8.2%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 6.5%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Çì¸ð±Û·Îºó A1C(HbA1C) °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Çì¸ð±Û·Îºó A1C(HbA1C) °Ë»ç´Â ´ç´¢º´ °ü¸®¸¦ À§ÇÑ Áß¿äÇÑ Áø´Ü µµ±¸·Î, Áö³­ 2-3°³¿ù°£ÀÇ Ç÷´ç ¼öÄ¡¸¦ Àå±âÀûÀÎ ÁöÇ¥·Î Á¦°øÇÕ´Ï´Ù. ÇöÀç Ç÷´ç ¼öÄ¡ÀÇ ½º³À¼¦À» ÃøÁ¤ÇÏ´Â ÀÏ¹Ý Ç÷´ç °Ë»ç¿Í ´Þ¸® HbA1c °Ë»ç´Â Ç÷¾× ³» ´çÈ­Ç÷»ö¼ÒÀÇ ºñÀ²À» ÃøÁ¤ÇÏ¿© Æò±Õ Ç÷´ç ¼öÄ¡¸¦ ¹Ý¿µÇÕ´Ï´Ù. ÀÌ °Ë»ç´Â ´ç´¢º´ Áø´Ü, Ä¡·á °èȹÀÇ È¿°ú Æò°¡, ¾à¹° Ä¡·á ¹× ÇÊ¿äÇÑ »ýȰ ½À°ü Á¶Á¤¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀÇ·áÁø°ú ȯÀÚ°¡ Ç÷´ç Á¶ÀýÀ» º¸´Ù È¿°úÀûÀ¸·Î ¸ð´ÏÅ͸µÇÏ°í ´ç´¢º´°ú °ü·ÃµÈ ÇÕº´Áõ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

´ç´¢º´ °ü¸®¿¡¼­ HbA1c °Ë»çÀÇ Á߿伺Àº ¾Æ¹«¸® °­Á¶Çصµ Áö³ªÄ¡Áö ¾Ê´Âµ¥, HbA1c °Ë»ç´Â ȯÀÚÀÇ Ç÷´ç ¼öÄ¡°¡ Àå±âÀûÀ¸·Î ¾ó¸¶³ª Àß °ü¸®µÇ°í ÀÖ´ÂÁö¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÒ ¼ö Àֱ⠶§¹®ÀÔ´Ï´Ù. ÀÌ °Ë»ç´Â ÀϹÝÀûÀ¸·Î ´ç´¢º´ ȯÀÚ¿¡°Ô´Â 3-6°³¿ù¸¶´Ù ½ÃÇàÇÏ´Â °ÍÀÌ ±ÇÀåµÇÁö¸¸, ÀϹÝÀÎÀÇ Àü´ç´¢º´°ú ´ç´¢º´ÀÇ ¼±º° ¹× Áø´Ü¿¡µµ »ç¿ëµË´Ï´Ù. °Ë»ç ±â¼úÀÇ ¹ßÀüÀ¸·Î HbA1c °Ë»ç´Â ´õ Á¤È®Çϰí, ´õ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°í, ´õ Æí¸®ÇØÁ³½À´Ï´Ù. ¶ÇÇÑ, °¡Á¤¿ë °Ë»ç ŰƮ°¡ Ãâ½ÃµÇ¾î ȯÀÚ°¡ ÀÚ½ÅÀÇ »óŸ¦ º¸´Ù Àû±ØÀûÀ¸·Î ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

Çì¸ð±Û·Îºó A1C(HbA1C) °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ù°, Àü ¼¼°èÀûÀ¸·Î ´ç´¢º´ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ´ç´¢º´À» È¿°úÀûÀ¸·Î °ü¸®Çϰí Áø´ÜÇϱâ À§ÇÑ Á¤±âÀûÀÎ HbA1c °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. µÑ°, Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î HbA1c °Ë»çÀÇ Á¤È®µµ¿Í Á¢±Ù¼ºÀÌ Çâ»óµÇ¾î ÀÓ»ó°ú °¡Á¤ ¸ðµÎ¿¡¼­ HbA1c °Ë»çÀÇ µµÀÔÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¼Â°, ¿¹¹æÀû °Ç°­°ü¸®¿Í ´ç´¢º´ Á¶±â Áø´Ü¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ´ç´¢º´ °ü¸® ÇÁ·Î±×·¥ÀÇ Áß¿äÇÑ ±¸¼º ¿ä¼Ò·Î HbA1c °Ë»ç ½ÃÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ´ç´¢º´°ú ±× ÇÕº´Áõ¿¡ ´ëÇÑ Àνİú ±³À°ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó À§Ç豺¿¡ ´ëÇÑ °Ë»ç ºóµµ¿Í Àϰü¼ºÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇյǾî HbA1c °Ë»ç ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀå°ú Á߿伺À» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

±â¼ú(À̿ ±³È¯ °í¼Ó ¾×ü Å©·Î¸¶Åä±×·¡ÇÇ(HPLC), ¸é¿ªºÐ¼®¹ý, ºØ»ê¿° ģȭ¼º Å©·Î¸¶Åä±×·¡ÇÇ, Á÷Á¢ È¿¼Ò ¾î¼¼ÀÌ, ±âŸ ±â¼ú), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø ¹× Ŭ¸®´Ð, Áø´Ü½ÇÇè½Ç, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 110°³»ç)

AI ÅëÇÕ

Global Industry Analysts´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Hemoglobin A1C (HbA1C) Testing Market to Reach US$2.3 Billion by 2030

The global market for Hemoglobin A1C (HbA1C) Testing estimated at US$1.5 Billion in the year 2024, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 8.1% over the analysis period 2024-2030. Ion-Exchange High Performance Liquid Chromatography (HPLC), one of the segments analyzed in the report, is expected to record a 8.6% CAGR and reach US$915.7 Million by the end of the analysis period. Growth in the Immunoassays segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.0 Million While China is Forecast to Grow at 10.6% CAGR

The Hemoglobin A1C (HbA1C) Testing market in the U.S. is estimated at US$422.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$274.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.2% and 8.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Hemoglobin A1C (HbA1c) Testing Market - Key Trends & Drivers Summarized

Hemoglobin A1C (HbA1c) testing is a crucial diagnostic tool for managing diabetes, providing a long-term indicator of blood glucose levels over the past two to three months. Unlike regular blood glucose tests that measure a snapshot of current blood sugar levels, HbA1c tests reflect the average blood glucose levels by measuring the percentage of glycated hemoglobin in the blood. This test is essential for diagnosing diabetes, assessing the effectiveness of treatment plans, and making necessary adjustments to medication or lifestyle. It helps healthcare providers and patients monitor glycemic control more effectively, thereby reducing the risk of diabetes-related complications.

The importance of HbA1c testing in diabetes management cannot be overstated, as it provides comprehensive insights into how well a patient's blood sugar levels are being managed over time. The test is typically recommended every three to six months for individuals with diabetes, but it is also used for screening and diagnosing prediabetes and diabetes in the general population. Advances in testing technology have made HbA1c tests more accurate, accessible, and convenient, with point-of-care testing devices enabling quicker results in clinical settings. Additionally, home testing kits have become available, empowering patients to monitor their condition more proactively.

The growth in the Hemoglobin A1C (HbA1c) testing market is driven by several factors. Firstly, the rising prevalence of diabetes worldwide is increasing the demand for regular HbA1c testing to manage and diagnose the condition effectively. Secondly, advancements in diagnostic technology are making HbA1c tests more accurate and accessible, enhancing their adoption in both clinical and home settings. Thirdly, the growing emphasis on preventive healthcare and early diagnosis of diabetes is driving the market for HbA1c testing as a key component of diabetes management programs. Lastly, increasing awareness and education about diabetes and its complications are encouraging more frequent and consistent testing among at-risk populations. These factors collectively ensure the continued growth and importance of the HbA1c testing market.

SCOPE OF STUDY:

The report analyzes the Hemoglobin A1C (HbA1C) Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Technology (Ion-Exchange High Performance Liquid Chromatography (HPLC), Immunoassays, Boronate Affinity Chromatography, Direct Enzymatic Assays, Other Technologies); End-Use (Hospitals & Clinics, Diagnostic Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 110 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â